{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:52:12Z","timestamp":1740135132936,"version":"3.37.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100005688","name":"Gottfried und Julia Bangerter-Rhyner-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005688","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["IZ07Z0_160876\/1"],"award-info":[{"award-number":["IZ07Z0_160876\/1"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Janggen-P\u00f6hn Foundation Switzerland"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12879-018-2979-y","type":"journal-article","created":{"date-parts":[[2018,2,12]],"date-time":"2018-02-12T13:13:16Z","timestamp":1518441196000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["SESOTHO trial (\u201cSwitch Either near Suppression Or THOusand\u201d) \u2013 switch to second-line versus WHO-guided standard of care for unsuppressed patients on first-line ART with viremia below 1000\u00a0copies\/mL: protocol of a multicenter, parallel-group, open-label, randomized clinical trial in Lesotho, Southern Africa"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1716-993X","authenticated-orcid":false,"given":"Alain","family":"Amstutz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bienvenu Lengo","family":"Nsakala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"Vanobberghen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josephine","family":"Muhairwe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracy Ren\u00e9e","family":"Glass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Achieng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamorena","family":"Sepeka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katleho","family":"Tlali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lebohang","family":"Sao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyaw","family":"Thin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Klimkait","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Battegay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niklaus Daniel","family":"Labhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,12]]},"reference":[{"key":"2979_CR1","unstructured":"UNAIDS. 90\u201390-90 An ambitious treatment target to help end the AIDS epidemic. http:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/90-90-90_en_0.pdf . Accessed 10 Apr 2016."},{"key":"2979_CR2","unstructured":"WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection; Recommendations for a public health approach - Second edition June 2016. http:\/\/apps.who.int\/iris\/bitstream\/10665\/208825\/1\/9789241549684_eng.pdf?ua=1 . Accessed 3 Oct 2016."},{"key":"2979_CR3","unstructured":"WHO. WHO. What\u2019s new in treatment monitoring: viral load and cd4 testing. UPDATE JULY 2017. http:\/\/apps.who.int\/iris\/bitstream\/10665\/255891\/1\/WHO-HIV-2017.22-eng.pdf?ua=1 . Accessed 24 July 2017."},{"key":"2979_CR4","unstructured":"Lesotho 2016 National ART Guidelines. https:\/\/www.childrenandaids.org\/sites\/default\/files\/2017-04\/Lesotho_ART-Guidelines_2016.pdf ."},{"key":"2979_CR5","unstructured":"2015_eacsguidelines_8_0-english_rev-20160124.pdf. http:\/\/www.eacsociety.org\/files\/2015_eacsguidelines_8_0-english_rev-20160124.pdf . Accessed 28 Mar 2016."},{"issue":"2","key":"2979_CR6","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1001\/jama.2016.8900","volume":"316","author":"HF G\u00fcnthard","year":"2016","unstructured":"G\u00fcnthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of hiv infection in adults: 2016 recommendations of the international antiviral society\u2013usa panel. JAMA. 2016;316(2):191\u2013210. https:\/\/doi.org\/10.1001\/jama.2016.8900 .","journal-title":"JAMA"},{"issue":"11","key":"2979_CR7","doi-asserted-by":"publisher","first-page":"5998","DOI":"10.1128\/AAC.01217-12","volume":"56","author":"JZ Li","year":"2012","unstructured":"Li JZ, Gallien S, Do TD, et al. Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia. Antimicrob Agents Chemother. 2012;56(11):5998\u20136000. https:\/\/doi.org\/10.1128\/AAC.01217-12 .","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"2979_CR8","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/infdis\/jir353","volume":"204","author":"B Taiwo","year":"2011","unstructured":"Taiwo B, Gallien S, Aga E, et al. Antiretroviral drug resistance in HIV-1\u2013infected patients experiencing persistent low-level viremia during first-line therapy. J Infect Dis. 2011;204(4):515\u201320. https:\/\/doi.org\/10.1093\/infdis\/jir353 .","journal-title":"J Infect Dis"},{"issue":"7","key":"2979_CR9","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.1128\/AAC.00076-14","volume":"58","author":"P Ryscavage","year":"2014","unstructured":"Ryscavage P, Kelly S, Li JZ, Harrigan PR, Taiwo B. Significance and clinical Management of Persistent low-Level Viremia and Very-low-Level Viremia in HIV-1-infected patients. Antimicrob Agents Chemother. 2014;58(7):3585\u201398. https:\/\/doi.org\/10.1128\/AAC.00076-14 .","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"2979_CR10","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1097\/QAD.0000000000000203","volume":"28","author":"LC Swenson","year":"2014","unstructured":"Swenson LC, Min JE, Woods CK, et al. HIV drug resistance detected during low-level viremia is associated with subsequent Virologic failure. AIDS Lond Engl. 2014;28(8):1125\u201334. https:\/\/doi.org\/10.1097\/QAD.0000000000000203 .","journal-title":"AIDS Lond Engl."},{"issue":"14","key":"2979_CR11","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1097\/00002030-200209270-00017","volume":"16","author":"G Greub","year":"2002","unstructured":"Greub G, Cozzi-Lepri A, Ledergerber B, et al. Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS. 2002;16(14):1967\u20139.","journal-title":"AIDS"},{"issue":"7","key":"2979_CR12","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1177\/135965350801300707","volume":"13","author":"AM Geretti","year":"2008","unstructured":"Geretti AM, Smith C, Haberl A, et al. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy. Antivir Ther. 2008;13(7):927\u201336.","journal-title":"Antivir Ther"},{"issue":"3","key":"2979_CR13","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1097\/QAD.0000000000000544","volume":"29","author":"M-A Vandenhende","year":"2015","unstructured":"Antiretroviral Therapy Cohort Collaboration (ART-CC), Vandenhende M-A, Ingle S, et al. Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients. AIDS Lond Engl. 2015;29(3):373\u201383. https:\/\/doi.org\/10.1097\/QAD.0000000000000544 .","journal-title":"AIDS Lond Engl"},{"issue":"3","key":"2979_CR14","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/jac\/dkm516","volume":"61","author":"P Garc\u00eda-Gasc\u00f3","year":"2008","unstructured":"Garc\u00eda-Gasc\u00f3 P, Maida I, Blanco F, et al. Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome. J Antimicrob Chemother. 2008;61(3):699\u2013704. https:\/\/doi.org\/10.1093\/jac\/dkm516 .","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"2979_CR15","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1093\/cid\/cit529","volume":"57","author":"C Laprise","year":"2013","unstructured":"Laprise C, de Pokomandy A, Baril J-G, Dufresne S, Trottier H. Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation. Clin Infect Dis. 2013;57(10):1489\u201396. https:\/\/doi.org\/10.1093\/cid\/cit529 .","journal-title":"Clin Infect Dis"},{"key":"2979_CR16","doi-asserted-by":"publisher","unstructured":"Hermans LE, Moorhouse M, Carmona S, et al. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided south African treatment programmes: a multicentre cohort study. Lancet Infect Dis. https:\/\/doi.org\/10.1016\/S1473-3099(17)30681-3 .","DOI":"10.1016\/S1473-3099(17)30681-3"},{"key":"2979_CR17","doi-asserted-by":"publisher","unstructured":"Labhardt ND, Bader J, Lejone TI, et al. Should viral load thresholds be lowered?: revisiting the WHO definition for virologic failure in patients on antiretroviral therapy in resource-limited settings. Medicine (Baltimore). 2016;95(28):e3985. https:\/\/doi.org\/10.1097\/MD.0000000000003985","DOI":"10.1097\/MD.0000000000003985"},{"key":"2979_CR18","doi-asserted-by":"crossref","unstructured":"Labhardt ND, Ringera I, Lejone TI, et al. When patients fail UNAIDS\u2019 last 90 - the \u201cfailure cascade\u201d beyond 90-90-90 in rural Lesotho, southern Africa: a prospective cohort study. J Int AIDS Soc. 2017;20(1):2017.","DOI":"10.7448\/IAS.20.1.21803"},{"issue":"2","key":"2979_CR19","doi-asserted-by":"publisher","first-page":"e55747","DOI":"10.1371\/journal.pone.0055747","volume":"8","author":"MR Loutfy","year":"2013","unstructured":"Loutfy MR, Wu W, Letchumanan M, et al. Systematic review of HIV transmission between heterosexual Serodiscordant couples where the HIV-positive partner is fully suppressed on antiretroviral therapy. PLoS One. 2013;8(2):e55747. https:\/\/doi.org\/10.1371\/journal.pone.0055747 .","journal-title":"PLoS One"},{"key":"2979_CR20","doi-asserted-by":"publisher","first-page":"20061","DOI":"10.7448\/IAS.18.1.20061","volume":"18","author":"N Ford","year":"2015","unstructured":"Ford N, Stinson K, Gale H, et al. CD4 changes among virologically suppressed patients on antiretroviral therapy: a systematic review and meta-analysis. J Int AIDS Soc. 2015;18:20061.","journal-title":"J Int AIDS Soc"},{"issue":"5","key":"2979_CR21","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1086\/655761","volume":"51","author":"A Mocroft","year":"2010","unstructured":"Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE), Mocroft A, Reiss P, et al. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells\/microL? Clin Infect Dis Off Publ Infect Dis Soc Am. 2010;51(5):611\u20139. https:\/\/doi.org\/10.1086\/655761 .","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"2979_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/jia2.25007","volume":"20","author":"TM Ellman","year":"2017","unstructured":"Ellman TM, Alemayehu B, Abrams EJ, Arpadi S, Howard AA, El-Sadr WM. Selecting a viral load threshold for routine monitoring in resource-limited settings: optimizing individual health and population impact. J Int AIDS Soc. 2017;20:16\u20138. https:\/\/doi.org\/10.1002\/jia2.25007 .","journal-title":"J Int AIDS Soc"},{"key":"2979_CR23","unstructured":"Lesotho Demographic and Health Survey 2014 [FR309] - FR309.pdf. http:\/\/dhsprogram.com\/pubs\/pdf\/FR309\/FR309.pdf . Accessed 30 July 2016."},{"key":"2979_CR24","doi-asserted-by":"publisher","unstructured":"Ajose O, Mookerjee S, Mills EJ, Boulle A, Ford N. Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. AIDS. 2012;26 https:\/\/doi.org\/10.1097\/QAD.0b013e328351f5b2 .","DOI":"10.1097\/QAD.0b013e328351f5b2"},{"issue":"6","key":"2979_CR25","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1093\/infdis\/jiw219","volume":"214","author":"TS Boender","year":"2016","unstructured":"Boender TS, Hamers RL, Ondoa P, et al. Protease inhibitor resistance in the first 3 years of second-line antiretroviral therapy for HIV-1 in sub-Saharan Africa. J Infect Dis. 2016;214(6):873\u201383. https:\/\/doi.org\/10.1093\/infdis\/jiw219 .","journal-title":"J Infect Dis"},{"issue":"1","key":"2979_CR26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1742-6405-11-18","volume":"11","author":"N Chkhartishvili","year":"2014","unstructured":"Chkhartishvili N, Sharvadze L, Dvali N, et al. Virologic outcomes of second-line antiretroviral therapy in eastern European country of Georgia. AIDS Res Ther. 2014;11(1):18. https:\/\/doi.org\/10.1186\/1742-6405-11-18 .","journal-title":"AIDS Res Ther"},{"issue":"5","key":"2979_CR27","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1093\/infdis\/jit411","volume":"209","author":"V Johnston","year":"2014","unstructured":"Johnston V, Cohen K, Wiesner L, et al. Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch. J Infect Dis. 2014;209(5):711\u201320. https:\/\/doi.org\/10.1093\/infdis\/jit411 .","journal-title":"J Infect Dis"},{"issue":"3","key":"2979_CR28","doi-asserted-by":"publisher","first-page":"e90772","DOI":"10.1371\/journal.pone.0090772","volume":"9","author":"C Kityo","year":"2014","unstructured":"Kityo C, Gibb DM, Gilks CF, et al. High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial. PLoS One. 2014;9(3):e90772. https:\/\/doi.org\/10.1371\/journal.pone.0090772 .","journal-title":"PLoS One"},{"key":"2979_CR29","doi-asserted-by":"publisher","first-page":"c332","DOI":"10.1136\/bmj.c332","volume":"340","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. The BMJ. 2010;340:c332. https:\/\/doi.org\/10.1136\/bmj.c332 .","journal-title":"The BMJ"},{"issue":"19","key":"2979_CR30","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1002\/sim.1296","volume":"21","author":"SJ Pocock","year":"2002","unstructured":"Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practiceand problems. Stat Med. 2002;21(19):2917\u201330. https:\/\/doi.org\/10.1002\/sim.1296 .","journal-title":"Stat Med"},{"key":"2979_CR31","unstructured":"UNAIDS. Joint United Nations Programme on HIV\/AIDS (UNAIDS). ENDING AIDS - progress towards the 90-90-90 targets. GLOBAL AIDS Update 2017. http:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/Global_AIDS_update_2017_en.pdf . Accessed 24 July 2017."},{"key":"2979_CR32","doi-asserted-by":"publisher","unstructured":"Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. The Lancet. 368(9534):505\u201310. https:\/\/doi.org\/10.1016\/S0140-6736(06)69158-7 .","DOI":"10.1016\/S0140-6736(06)69158-7"},{"key":"2979_CR33","unstructured":"WHO. TASK SHIFTING: rational redistribution of tasks among health workforce teams. Global Recommendations and Guidelines. Accessed 27 May 2017. http:\/\/data.unaids.org\/pub\/manual\/2007\/ttr_taskshifting_en.pdf . Accessed 27 May 2017."},{"key":"2979_CR34","unstructured":"WHO. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach: 2010 revision. http:\/\/apps.who.int\/iris\/bitstream\/10665\/44379\/1\/9789241599764_eng.pdf . Accessed 26 July 2017."},{"key":"2979_CR35","unstructured":"WHO | Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. June 2013. http:\/\/www.who.int\/hiv\/pub\/guidelines\/arv2013\/en\/ . Accessed 28 Mar 2016."},{"key":"2979_CR36","unstructured":"MSF. Untangling The Web of Antiretroviral Price Reductions - 18th ed. July 2016. https:\/\/www.msfaccess.org\/sites\/default\/files\/HIV_report_Untangling-the-web-18thed_ENG_2016.pdf . Accessed 26 July 2017."},{"key":"2979_CR37","unstructured":"WHO. Antiretroviral Medicines in low- and middle-income countries: forecast of global and regional demand for 2013\u20132016. http:\/\/apps.who.int\/iris\/bitstream\/10665\/111626\/1\/9789241507004_eng.pdf . Accessed 26 July 2017."},{"issue":"11","key":"2979_CR38","first-page":"16","volume":"29","author":"SS Sutton","year":"2016","unstructured":"Sutton SS, Ahuja D, Magagnoli J. What is the effect of pill burden on adherence to HIV antiretroviral therapy? J Am Acad PAs. 2016;29(11):16\u20137.","journal-title":"J Am Acad PAs"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-2979-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,14]],"date-time":"2022-08-14T05:43:14Z","timestamp":1660455794000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-018-2979-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,12]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2979"],"URL":"https:\/\/doi.org\/10.1186\/s12879-018-2979-y","relation":{},"ISSN":["1471-2334"],"issn-type":[{"type":"electronic","value":"1471-2334"}],"subject":[],"published":{"date-parts":[[2018,2,12]]},"assertion":[{"value":"28 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This trial has been approved by the National Health Research and Ethics Committee of the Ministry of Health of Lesotho (ID48\u20132017, 05.07.2017) and the Ethics committee in Switzerland (Ethikkomission Nordwest- und Zentralschweiz; EKNZ BASEC UBE 2017\u201300201, 10.04.2017). Prior to randomization, all participants will provide oral and written informed consent: The study nurse\/physician will explain the information sheet to participants. Once all open questions have been clarified and upon agreement to participate, the participant will sign the informed consent form. Iliterate participants will provide a thumb-print and a witness (independent to the trial and >\u200921\u00a0years old), chosen by the participant, will co-sign the form. For children and young adults aged <\u200918\u00a0years, a literate caregiver >\u200921\u00a0years old (person that takes care of the child\/young adult) will provide oral and written informed consent. The informed consent is provided in English and the local language, Sesotho, and the participant will receive a copy of the consent form in written format to take away.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, under the lead of MB receives unrestricted education and research grants from Gilead, MSD, Janssen, and ViiV. All other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"76"}}